Defective apoptotic cell contractility provokes sterile inflammation, leading to liver damage and tumour suppression.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
19 04 2021
Historique:
received: 11 08 2020
accepted: 17 04 2021
pubmed: 20 4 2021
medline: 27 10 2021
entrez: 19 4 2021
Statut: epublish

Résumé

Apoptosis is characterized by profound morphological changes, but their physiological purpose is unknown. To characterize the role of apoptotic cell contraction, ROCK1 was rendered caspase non-cleavable (ROCK1nc) by mutating aspartate 1113, which revealed that ROCK1 cleavage was necessary for forceful contraction and membrane blebbing. When homozygous ROCK1nc mice were treated with the liver-selective apoptotic stimulus of diethylnitrosamine, ROCK1nc mice had more profound liver damage with greater neutrophil infiltration than wild-type mice. Inhibition of the damage-associated molecular pattern protein HMGB1 or signalling by its cognate receptor TLR4 lowered neutrophil infiltration and reduced liver damage. ROCK1nc mice also developed fewer diethylnitrosamine-induced hepatocellular carcinoma (HCC) tumours, while HMGB1 inhibition increased HCC tumour numbers. Thus, ROCK1 activation and consequent cell contraction are required to limit sterile inflammation and damage amplification following tissue-scale cell death. Additionally, these findings reveal a previously unappreciated role for acute sterile inflammation as an efficient tumour-suppressive mechanism.

Identifiants

pubmed: 33871359
doi: 10.7554/eLife.61983
pii: 61983
pmc: PMC8087448
doi:
pii:

Substances chimiques

HMGB1 Protein 0
HMGB1 protein, mouse 0
Myosin Light Chains 0
Sulfonamides 0
Tlr4 protein, mouse 0
Toll-Like Receptor 4 0
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate 0
Diethylnitrosamine 3IQ78TTX1A
Glycyrrhizic Acid 6FO62043WK
Rock1 protein, mouse EC 2.7.11.1
rho-Associated Kinases EC 2.7.11.1
Caspases EC 3.4.22.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : PJT-169106
Pays : Canada
Organisme : Cancer Research UK
ID : A17196
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A10419
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A18276
Pays : United Kingdom

Informations de copyright

© 2021, Julian et al.

Déclaration de conflit d'intérêts

LJ, GN, GW, NR, GC, DS, SB, JM, LM, MM, AR, AD, MO No competing interests declared

Références

Nat Cell Biol. 2001 Apr;3(4):339-45
pubmed: 11283606
Carcinogenesis. 1991 Jun;12(6):1137-41
pubmed: 2044196
Mol Biol Cell. 2013 Mar;24(6):748-56
pubmed: 23345589
J Cell Biol. 2005 Jan 17;168(2):245-55
pubmed: 15657395
J Surg Oncol. 1986 Apr;31(4):229-34
pubmed: 3724177
J Clin Invest. 2015 Feb;125(2):539-50
pubmed: 25562324
Nat Rev Dis Primers. 2020 Jan 23;6(1):7
pubmed: 31974366
Curr Biol. 2015 Jun 1;25(11):1520-5
pubmed: 25981793
Mol Oncol. 2013 Apr;7(2):206-23
pubmed: 23428636
Mol Pharmacol. 2006 Apr;69(4):1288-95
pubmed: 16373689
Nat Rev Immunol. 2020 Apr;20(4):254-267
pubmed: 31822793
FEBS Lett. 1997 Mar 10;404(2-3):118-24
pubmed: 9119047
Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S421-6
pubmed: 16237641
Science. 2004 May 21;304(5674):1147-50
pubmed: 15155946
Cell Death Differ. 2012 May;19(5):735-42
pubmed: 22421963
Gastroenterology. 2008 May;134(6):1641-54
pubmed: 18471544
Apoptosis. 2002 Aug;7(4):321-8
pubmed: 12101391
Semin Cancer Biol. 2004 Dec;14(6):473-86
pubmed: 15489140
Int J Mol Sci. 2019 Oct 25;20(21):
pubmed: 31731454
IARC Sci Publ. 1999;(146):273-85
pubmed: 10353391
Cell Death Differ. 2002 May;9(5):493-504
pubmed: 11973608
Nat Cell Biol. 2001 Apr;3(4):346-52
pubmed: 11283607
Toxicol Pathol. 2007 Jun;35(4):495-516
pubmed: 17562483
Nat Immunol. 2003 Feb;4(2):138-44
pubmed: 12524536
Nat Genet. 1998 May;19(1):56-9
pubmed: 9590289
J Cell Biol. 2010 Jun 28;189(7):1059-70
pubmed: 20584912
Nat Commun. 2015 Dec 01;6:10029
pubmed: 26620183
Carcinogenesis. 1993 Aug;14(8):1603-8
pubmed: 8353844
Therap Adv Gastroenterol. 2019 Jan 22;12:1756284818821560
pubmed: 30719075
Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):911-5
pubmed: 1992483
Genome Res. 2004 Apr;14(4):708-15
pubmed: 15060014
Cancer Res. 2007 Dec 1;67(23):11141-6
pubmed: 18056438
Hepatol Commun. 2019 Apr 22;3(6):730-743
pubmed: 31168508
Genes Cells. 2004 Jun;9(6):591-600
pubmed: 15189451
Cell Death Differ. 2010 Mar;17(3):381-97
pubmed: 20019744
J Cell Biol. 1998 Feb 9;140(3):627-36
pubmed: 9456322
Lab Anim. 2015 Apr;49(1 Suppl):59-69
pubmed: 25835739
Genomics. 2001 Apr 1;73(1):56-65
pubmed: 11352566
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13642-7
pubmed: 9391079
Cell. 2010 Mar 5;140(5):619-30
pubmed: 20211132
Am J Pathol. 2018 Jun;188(6):1316-1327
pubmed: 29673755
Genome Res. 2003 Mar;13(3):476-84
pubmed: 12618378
Mol Cell. 2011 Dec 23;44(6):878-92
pubmed: 22137581
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4455-60
pubmed: 17360545
Methods Enzymol. 2009;461:379-96
pubmed: 19480928
J Natl Cancer Inst. 1984 Dec;73(6):1311-7
pubmed: 6595442
J Cell Sci. 1998 Oct;111 ( Pt 19):2911-22
pubmed: 9730983
Exp Cell Res. 2006 Oct 15;312(17):3298-311
pubmed: 16904666
Annu Rev Immunol. 2018 Apr 26;36:489-517
pubmed: 29400998
Nat Commun. 2016 Sep 07;7:12630
pubmed: 27600527
Cancer Res. 2018 Apr 15;78(8):2096-2114
pubmed: 29382705
Exp Cell Res. 2006 Jan 1;312(1):5-15
pubmed: 16259978
Science. 2014 Jun 6;344(6188):1164-8
pubmed: 24904167
Cell Death Differ. 2013 Oct;20(10):1293-305
pubmed: 23787996
Toxicol Pathol. 2006;34(5):466-503
pubmed: 17067940
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Cell Commun Signal. 2014 Oct 05;12:54
pubmed: 25288205
Br J Cancer. 1972 Aug;26(4):239-57
pubmed: 4561027
Science. 1997 Jun 6;276(5318):1571-4
pubmed: 9171063
Expert Rev Mol Med. 2012 Feb 03;14:e4
pubmed: 22306029
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890
Chem Biol. 2007 Apr;14(4):431-41
pubmed: 17462578
Nature. 2020 Jan;577(7788):103-108
pubmed: 31827281
Nat Rev Mol Cell Biol. 2020 Jul;21(7):398-414
pubmed: 32251387
Eur J Immunol. 1981 Oct;11(10):805-15
pubmed: 7308288

Auteurs

Linda Julian (L)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.
Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Gregory Naylor (G)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.
Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Grant R Wickman (GR)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.
Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Nicola Rath (N)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.

Giovanni Castino (G)

Department of Chemistry and Biology, Ryerson University, Toronto, Canada.

David Stevenson (D)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.

Sheila Bryson (S)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.

June Munro (J)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.

Lynn McGarry (L)

Cancer Research United Kingdom Beatson Institute, Garscube Estate, Glasgow, United Kingdom.

Margaret Mullin (M)

Electron Microscopy Facility, School of Life Sciences, University of Glasgow, Glasgow, United Kingdom.

Alistair Rice (A)

Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Imperial College London, London, United Kingdom.

Armandodel Del Río Hernández (A)

Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Imperial College London, London, United Kingdom.

Michael F Olson (MF)

Department of Chemistry and Biology, Ryerson University, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH